Navigation Links
ZFP in Medical News
Sangamo BioSciences Presents Positive Phase 2 ZFP Therapeutic Data at ADA 2009
Analysis of Subjects with Moderately Severe Diabetic Neuropathy Shows Statistically Significant Improvement in Multiple Quantitative Neurological Endpoints RICHMOND, Calif., June 8 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO ) announced today the presentation of as y...Sangamo BioSciences Announces Presentation at the JMP Securities Research Conference
...ill provide an update on the progress of Sangamo's zfp Therapeutic(TM) development programs and an overvi...ene regulation and modification. The most advanced zfp Therapeutic(TM) development program is currently i... trial to evaluate safety and clinical effect of a zfp Therapeutic for the treatment of HIV/AIDS. Other t...Sangamo BioSciences Reports First Quarter 2009 Financial Results
...n in Nature of the successful application of zfp technology for the efficient generation of maize p...ene regulation and modification. The most advanced zfp Therapeutic(TM) development program is currently i... trial to evaluate safety and clinical effect of a zfp Therapeutic for the treatment of HIV/AIDS. Other t...Sangamo BioSciences Provides Update on Company's Accomplishments in 2007 and 2008 Objectives
...ve had together to confirm our conviction that the zfp platform has the ability to truly transform the fi... Mr. Peribere. "We have established that Sangamo's zfp technology can be used to regulate and modify gene... clinical data from our Phase 1b trial of our lead zfp Therapeutic(TM), SB-509, an activator of vascular ...Sangamo BioSciences to Present at the ThinkEquity Partners Growth Conference
...ill provide an update on the progress of Sangamo's zfp Therapeutic development programs and an overview o...ene regulation and modification. The most advanced zfp Therapeutic(TM) development program is currently i... Phase 1 clinical trials are ongoing to evaluate a zfp Therapeutic for peripheral artery disease. Other t...New Gene Therapy Treats Diabetic Neuropathy
...Faculty of Life Sciences. ‘Our approach to gene therapy is quite different to previous attempts at treatment: we use a DNA-binding protein called zfp TFTM to poke life into the patient's own genes and produce a growth factor that has a role in nerve protection and regeneration. ‘As the data in ...ZFP in Medical Technology
Presentation Details Statistically Significant and Clinically Relevant
Results for SB-509 in Development for Treatment of Diabetic Neuropathy
SAN FRANCISCO, June 8 /PRNewswire-FirstCall/ -- Sangamo BioSciences,
Inc. (Nasdaq: SGMO ) announced today the presentation of encouraging Phase
1b ...
ZFN Modified Cells Show Glioblastoma Killing in the Presence of Dexamethasone in Mouse Tumor Model SAN DIEGO, April 15 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO ) today announced the presentation of positive data in a mouse tumor model from its ZF...
Milestone Triggers Payment to Sangamo from JDRF RICHMOND, Calif., Dec. 4 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO ) announced today that the company has completed enrollment of its randomized, double-blind, repeat-dosing, placebo-controlled, multi-center P...
Statistically Significant Improvements in Function in Spinal Cord Injury Model With ZFP TF Treatment RICHMOND, Calif., May 03, 2007 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. announced today the presentation of preclinical data from its ZFP Therapeutic(TM) program in nerve regeneration at...
...ognize a specific DNA sequence Sangamo has created zfp transcription factors (ZFP TF(TM)) that can contro...tion. Sangamo is also developing sequence-specific zfp Nucleases (ZFN(TM)) for gene modification. The most advanced zfp Therapeutic(TM) development program is currently i...
...ene regulation and modification. The most advanced zfp Therapeutic(TM) development program is currently i...ognize a specific DNA sequence Sangamo has created zfp transcription factors (ZFP TF(TM)) that can contro...tion. Sangamo is also developing sequence-specific zfp Nucleases (ZFN(TM)) for gene modification. Sangamo...
...ene regulation and modification. The most advanced zfp Therapeutic(TM) development program is currently i... Phase 1 clinical trials are ongoing to evaluate a zfp Therapeutic for peripheral artery disease. Other t...tion. Sangamo is also developing sequence-specific zfp Nucleases (ZFN(TM)) for gene modification. Sangamo...
ZFN Modified Cells Show Glioblastoma Killing in the Presence of Dexamethasone in Mouse Tumor Model SAN DIEGO, April 15 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO ) today announced the presentation of positive data in a mouse tumor model from its ZF...
Milestone Triggers Payment to Sangamo from JDRF RICHMOND, Calif., Dec. 4 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO ) announced today that the company has completed enrollment of its randomized, double-blind, repeat-dosing, placebo-controlled, multi-center P...
Statistically Significant Improvements in Function in Spinal Cord Injury Model With ZFP TF Treatment RICHMOND, Calif., May 03, 2007 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. announced today the presentation of preclinical data from its ZFP Therapeutic(TM) program in nerve regeneration at...
Researchers Create First Targeted Knockout Rats Using Zinc Finger Nuclease Technology
...ne regulation and modification. The most advanced zfp Therapeutic(TM) development program is currently i... trial to evaluate safety and clinical effect of a zfp Therapeutic for the treatment of HIV/AIDS. Other t...ognize a specific DNA sequence Sangamo has created zfp transcription factors (ZFP TF(TM)) that can contro......ognize a specific DNA sequence Sangamo has created zfp transcription factors (ZFP TF(TM)) that can contro...tion. Sangamo is also developing sequence-specific zfp Nucleases (ZFN(TM)) for gene modification. The most advanced zfp Therapeutic(TM) development program is currently i...
Sangamo BioSciences Announces Presentations at Two Upcoming Investor Conferences
...ill provide an update on the progress of Sangamo's zfp Therapeutic(TM) development programs and an overvi...ne regulation and modification. The most advanced zfp Therapeutic(TM) development program is currently i... trial to evaluate safety and clinical effect of a zfp Therapeutic for the treatment of HIV/AIDS. Other t...Sangamo BioSciences Provides Update on Company's 2008 Progress and 2009 Objectives
... in laboratories worldwide and we expect Sangamo's zfp technology to be nothing short of revolutionary fo...past year has been a year of real progress for our zfp technology platform," said Edward Lanphier, presid...us to make significant progress in moving our lead zfp Therapeutic into multiple Phase 2 clinical trials ......ene regulation and modification. The most advanced zfp Therapeutic(TM) development program is currently i...ognize a specific DNA sequence Sangamo has created zfp transcription factors (ZFP TF(TM)) that can contro...tion. Sangamo is also developing sequence-specific zfp Nucleases (ZFN(TM)) for gene modification. Sangamo...
...ene regulation and modification. The most advanced zfp Therapeutic(TM) development program is currently i... Phase 1 clinical trials are ongoing to evaluate a zfp Therapeutic for peripheral artery disease. Other t...tion. Sangamo is also developing sequence-specific zfp Nucleases (ZFN(TM)) for gene modification. Sangamo...
ZFP in Biological News
Sangamo BioSciences demonstrates its ZFP treatment protects cells from HIV infection
Sangamo BioSciences, Inc. today announced that data from its program to develop a ZFP Therapeutic for HIV/AIDS were presented at the 45th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in Washington, DC. The study represents the first demonstration that cells can b...Sangamo BioSciences to Present at the Bank of America 2008 Healthcare Conference
...ene regulation and modification. The most advanced zfp Therapeutic(TM) development program is currently i... Phase 1 clinical trials are ongoing to evaluate a zfp Therapeutic for peripheral artery disease. Other t...ognize a specific DNA sequence Sangamo has created zfp transcription factors (ZFP TFTM) that can control ...Trial success for diabetic nerve therapy
...s Faculty of Life Sciences. "Our approach to gene therapy is quite different to previous attempts at treatment: we use a DNA-binding protein called zfp TFTM to poke life into the patient's own genes and produce a growth factor that has a role in nerve protection and regeneration. "As the data in th...ZFP in Biological Technology
Progenitor Cell Mobilization Observed in Subjects with Critical Limb Ischemia Treated with ZFP Therapeutic
MIAMI, May 19 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc.
(Nasdaq: SGMO ) announced today the presentation of data from a Phase 1
clinical trial of a zinc finge...
RICHMOND, Calif., April 7, 2008 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO ) today announced that it had entered into a License Agreement with Open Monoclonal Technologies (OMT), a private company based in Palo Alto, California. Under this agreement, Sangamo will provid...
Companies Agree to Expanded Access to ZFN Technology To Potentially Improve Protein Production RICHMOND, Calif., Feb. 27 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO ) today announced that it has entered into a second Research and License Agreement...
Statistically Significant Improvements in Function and Tissue Preservation with ZFP TF Treatment in Spinal Cord Injury Model SAN DIEGO, Nov. 7 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO ) announced today the presentation of preclinical data from its ZFP Therape...
...valuate the safety and tolerability of SB-728-T, a zfp Therapeutic based on Sangamo's CCR5-disrupting ZFN...our efforts to develop the next generation of this zfp Therapeutic, an in-vivo formulation for direct i...ne regulation and modification. The most advanced zfp Therapeutic(TM) development program is currently i...
...Sangamo demonstrated the successful application of zfp technology for the efficient generation of maize p... , scientists at Dow AgroSciences and Sangamo used zfp Nucleases (ZFNs(TM)) to introduce a herbicide tole...ul demonstration of the broad applicability of our zfp technology platform," stated Philip Gregory, D. Ph...
RICHMOND, Calif., April 7, 2008 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO ) today announced that it had entered into a License Agreement with Open Monoclonal Technologies (OMT), a private company based in Palo Alto, California. Under this agreement, Sangamo will provid...
Companies Agree to Expanded Access to ZFN Technology To Potentially Improve Protein Production RICHMOND, Calif., Feb. 27 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO ) today announced that it has entered into a second Research and License Agreement...
Statistically Significant Improvements in Function and Tissue Preservation with ZFP TF Treatment in Spinal Cord Injury Model SAN DIEGO, Nov. 7 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO ) announced today the presentation of preclinical data from its ZFP Therape...
Sangamo BioSciences Reports Second Quarter 2009 Financial Results
...hlights Presentation of positive Phase 2 zfp Therapeutic data at ADA 2009. Sangamo announced t...unreleased positive Phase 2 clinical data from its zfp Therapeutic(TM) program to develop SB-509 as a tre...angamo demonstrating the successful application of zfp technology for the efficient generation of maize p...Sangamo BioSciences Announces Second Quarter 2009 Conference Call and Webcast
...ognize a specific DNA sequence Sangamo has created zfp transcription factors (ZFP TF(TM)) that can contro...tion. Sangamo is also developing sequence-specific zfp Nucleases (ZFN(TM)) for gene modification. The most advanced zfp Therapeutic(TM) development program is currently i...Sangamo BioSciences Announces Presentation at the Needham Life Sciences Conference
...ill provide an update on the progress of Sangamo's zfp Therapeutic(TM) development programs and an overvi...ene regulation and modification. The most advanced zfp Therapeutic(TM) development program is currently i... trial to evaluate safety and clinical effect of a zfp Therapeutic for the treatment of HIV/AIDS. Other t......valuate the safety and tolerability of SB-728-T, a zfp Therapeutic based on Sangamo's CCR5-disrupting ZFN...our efforts to develop the next generation of this zfp Therapeutic, an in-vivo formulation for direct i...ne regulation and modification. The most advanced zfp Therapeutic(TM) development program is currently i...
...Sangamo demonstrated the successful application of zfp technology for the efficient generation of maize p... , scientists at Dow AgroSciences and Sangamo used zfp Nucleases (ZFNs(TM)) to introduce a herbicide tole...ul demonstration of the broad applicability of our zfp technology platform," stated Philip Gregory, D. Ph...
Sangamo BioSciences Announces First Quarter 2009 Conference Call and Webcast
...ne regulation and modification. The most advanced zfp Therapeutic(TM) development program is currently i... trial to evaluate safety and clinical effect of a zfp Therapeutic for the treatment of HIV/AIDS. Other t...ognize a specific DNA sequence Sangamo has created zfp transcription factors (ZFP TF(TM)) that can contro...Other TagsOther Contents
(Date:6/19/2013)... system for repairing damage to the genetic material DNA ... may seem, those compounds are sparking optimism as potential ... mutation in BRCA, a gene that made headlines when ... compounds, termed PARP inhibitors, are the topic of the ... & Engineering News . C&EN is the weekly news ...
(Date:6/19/2013)... Dental professionals are increasingly monitoring end tidal carbon ... sedation, a patient’s breathing depth and rate decrease. ... to update its guidelines to require etCO2 monitoring, or ... to increase safety in procedures. This amendment to Section ... effect July 1. , The Oregon Board of ...
(Date:6/19/2013)... DiscountFurnaceFilter.com, the number one solution for homeowner’s ... Compressor Saver kit at an exceptional price. The 5-2-1 Compressor ... air conditioning unit during start up, saving wear and tear ... unit burn out. , The 5-2-1 Compressor Saver ... uses less power to start and drastically reduces the rush ...
(Date:6/19/2013)... Scottsdale, AZ (PRWEB) June 19, 2013 Guests ... feel healthy, wealthy and wise even if they don’t go ... that does require some early thought. , ... pockets when they take advantage of the pet-friendly Scottsdale Paradise ... Percent Package . With at least 14 days advance notice, ...
(Date:6/19/2013)... Washington (PRWEB) June 19, 2013 ... physicians deem it medically necessary, according to a ... and Child Health Journal. The results of this ... for more than a decade – that trying-to-conceive ... and maintaining a healthy body weight. Fairhaven Health ...
Breaking Medicine News(10 mins):Health News:Required Capnography Monitoring Growing Trend Among National and State Healthcare Organizations 2Health News:Required Capnography Monitoring Growing Trend Among National and State Healthcare Organizations 3Health News:Plan Ahead and Save Big With New Deal From Residence Inn Scottsdale Paradise Valley 2Health News:Plan Ahead and Save Big With New Deal From Residence Inn Scottsdale Paradise Valley 3Health News:Plan Ahead and Save Big With New Deal From Residence Inn Scottsdale Paradise Valley 4Health News:Fairhaven Health's Dr. Amos Grunebaum Says Fertility Awareness Leads to Babies 2Health News:Fairhaven Health's Dr. Amos Grunebaum Says Fertility Awareness Leads to Babies 3Health News:Fairhaven Health's Dr. Amos Grunebaum Says Fertility Awareness Leads to Babies 4[0] Renewed hope in a once-abandoned cancer drug class[0] Required Capnography Monitoring Growing Trend Among National and State Healthcare Organizations[0] DiscountFurnaceFilter.Com is Pleased to Offer the 5-2-1 Compressor Saver Kit at an Exceptional Price[0] Plan Ahead and Save Big With New Deal From Residence Inn Scottsdale Paradise Valley[0] Fairhaven Health's Dr. Amos Grunebaum Says Fertility Awareness Leads to Babies
(Date:6/18/2013)... engineer has been awarded a $394,300 grant from ... quality and flow in the new facilities of ... UT Arlington associate professor of civil engineering, will ... monochloramine to the water in an effort to ... and pipelines. Adding monochloramine is widely practiced throughout ...
(Date:6/18/2013)... a very large "dead zone" in the Gulf of ... the Chesapeake Bay this year, based on several NOAA-supported ... Michigan, Louisiana State University, and the Louisiana Universities ... Mexico hypoxic "dead" zone will be between 7,286 and ... ten largest recorded. That would range from an area ...
(Date:6/18/2013)... The National Institutes of Health has awarded $12.7 ... a selection of pharmaceutical industry compounds to explore ... including Alzheimer,s disease, Duchenne muscular dystrophy and schizophrenia. ... Uses for Existing Molecules, is led by the ... funded by the NIH Common Fund. , The ...
Breaking Biology News(10 mins):UT Arlington research to benefit quality, flow in 150-mile Integrated Pipeline 2NOAA, partners predict possible record-setting deadzone for Gulf of Mexico 2NOAA, partners predict possible record-setting deadzone for Gulf of Mexico 3NOAA, partners predict possible record-setting deadzone for Gulf of Mexico 4NIH to fund collaborations with industry to identify new uses for existing compounds 2NIH to fund collaborations with industry to identify new uses for existing compounds 3NIH to fund collaborations with industry to identify new uses for existing compounds 4| Copyright © 2003-2012 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |